AtriCure (ATRC)

The company’s portfolio includes radiofrequency ablation systems, cryoablation products, soft-tissue dissection tools, pacing and sensing devices, and related surgical accessories. AtriCure also offers left atrial appendage management products, which are used during open-heart and minimally invasive procedures to reduce risks associated with the left atrial appendage in certain patients. Its pain management solutions are used in cardiothoracic and thoracic surgery to freeze nerves and help manage post-operative pain.

AtriCure sells through a combination of direct sales representatives and distributors, with the United States accounting for the majority of revenue. Its customers include major medical centers and surgical programs, where product adoption depends on clinical evidence, physician training, reimbursement, and hospital purchasing decisions.

The company operates in a specialized segment of medtech that sits between cardiac surgery, electrophysiology, and pain management. Its differentiation comes from focusing on surgical Afib treatment and adjacent procedures rather than broad hospital equipment markets. Demand is influenced by procedure volumes, awareness of surgical ablation options, innovation in minimally invasive approaches, and the continued need for therapies addressing atrial fibrillation, one of the most common heart rhythm disorders.